Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Stock Has Consensus Target Price of $43.73

Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) have earned a consensus recommendation of “Moderate Buy” from the thirteen research firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $44.67.

TEVA has been the topic of several analyst reports. Wall Street Zen lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Barclays lifted their target price on shares of Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. Weiss Ratings cut shares of Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, September 8th. Oppenheimer assumed coverage on Teva Pharmaceutical Industries in a research note on Wednesday, September 23rd. They issued an “outperform” rating and a $50.00 price target on the stock. Finally, Piper Sandler raised their price target on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 28th.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA stock opened at $39.48 on Wednesday. The firm has a market cap of $46.01 billion, a price-to-earnings ratio of 65.80, a PEG ratio of 3.77 and a beta of 0.89. Teva Pharmaceutical Industries has a 12 month low of $18.83 and a 12 month high of $40.79. The company has a quick ratio of 0.67, a current ratio of 0.88 and a debt-to-equity ratio of 1.56. The stock has a 50-day moving average price of $37.04 and a 200 day moving average price of $34.15.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Tuesday, June 30th. The company reported $0.02 earnings per share (EPS) for the quarter. The company had revenue of $4.14 billion for the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. Research analysts expect that Teva Pharmaceutical Industries will post 1.93 EPS for the current year.

Insider Activity

In other news, insider Brian Savage sold 7,342 shares of the company’s stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $38.85, for a total value of $285,236.70. Following the completion of the sale, the insider directly owned 8,500 shares of the company’s stock, valued at $330,225. This represents a 46.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Roberto Mignone sold 367,600 shares of the stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $39.06, for a total transaction of $14,358,456.00. The disclosure for this sale is available in the SEC filing. Insiders sold 374,959 shares of company stock worth $14,644,285 in the last three months. Insiders own 0.54% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. QRG Capital Management Inc. increased its stake in Teva Pharmaceutical Industries by 17.0% in the second quarter. QRG Capital Management Inc. now owns 89,078 shares of the company’s stock valued at $3,018,000 after purchasing an additional 12,925 shares in the last quarter. Envestnet Portfolio Solutions Inc. boosted its position in shares of Teva Pharmaceutical Industries by 7.1% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 7,311 shares of the company’s stock worth $248,000 after purchasing an additional 483 shares in the last quarter. Bullseye Investment Management LLC acquired a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at $68,000. Sequoia Financial Advisors LLC grew its holdings in shares of Teva Pharmaceutical Industries by 12.5% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 190,940 shares of the company’s stock valued at $6,469,000 after buying an additional 21,240 shares during the period. Finally, National Pension Service grew its holdings in shares of Teva Pharmaceutical Industries by 4.9% in the 2nd quarter. National Pension Service now owns 2,406,013 shares of the company’s stock valued at $81,516,000 after buying an additional 112,357 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

Key Headlines Impacting Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Ecopipam data strengthen Teva’s pipeline prospects. New analyses showed that approximately 70% of pediatric Tourette syndrome patients experienced clinically meaningful tic reduction within eight weeks. An interim 18-month extension study showed a mean 45.6% reduction in tic-severity scores, with no new safety signals. The results support ecopipam’s potential as a differentiated, non-antipsychotic treatment, although it remains investigational and is not yet approved. Teva Presents New Efficacy and Safety Data with Ecopipam
• Positive Sentiment: Analyst sentiment improved. TD Cowen initiated coverage with a Buy rating and a $55 price target, implying substantial upside from the recent trading level. Separately, the reported consensus target increased 24.24% to approximately ₪41.82, reinforcing a favorable view of Teva’s valuation and growth outlook.
• Positive Sentiment: Biosimilar collaboration expands future growth opportunities. Teva and Samsung Bioepis agreed to develop and commercialize up to six biosimilar candidates globally, including candidates referencing Fasenra and Ilaris. The agreement could broaden Teva’s specialty-medicine pipeline and support longer-term revenue growth, though development and regulatory milestones remain ahead. Samsung Bioepis and Teva Expand Strategic Partnership
• Neutral Sentiment: A Journal of Child Neurology review highlighted ecopipam’s selective D1-receptor mechanism and potential advantages over antipsychotic therapies, but the review is supportive scientific context rather than new clinical or regulatory approval. Journal of Child Neurology Review

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. Founded in 1901, the company develops, manufactures and distributes generic medicines, specialty pharmaceuticals, active pharmaceutical ingredients and biosimilars.

Teva’s portfolio includes medicines for conditions affecting the central nervous system, respiratory system and other therapeutic areas. Its branded and specialty products include treatments such as Copaxone for multiple sclerosis, Austedo for movement disorders, Ajovy for migraine prevention and Uzedy for schizophrenia.